CSOP China Healthcare Disruption Index ETF (HKG:3174)
Hong Kong · Delayed Price · Currency is HKD 3.916
+0.160 (4.26%)
At close: Jul 29, 2025, 4:00 PM HKT
4.26% (1Y)
| Assets | 1.05B |
| Expense Ratio | 1.50% |
| PE Ratio | 24.83 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +131.44% |
| Volume | 582,400 |
| Open | 3.756 |
| Previous Close | 3.756 |
| Day's Range | 3.750 - 3.928 |
| 52-Week Low | 1.612 |
| 52-Week High | 3.916 |
| Beta | 0.53 |
| Holdings | 23 |
| Inception Date | Jul 21, 2021 |
About 3174
CSOP China Healthcare Disruption Index ETF is an exchange-traded fund directly investing in companies. It prefers to invest in companies based out of Hong Kong. It primarily invests the healthcare- pharmaceutical and medical device companies.
Asset Class Equity
Category Total Market
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3174
Provider CSOP
Index Tracked WISE Samsung Group Value Index- KRW - Benchmark Price Return
Performance
3174 had a total return of 131.44% in the past year, including dividends. Since the fund's inception, the average annual return has been -14.98%.
Top 10 Holdings
77.08% of assets| Name | Symbol | Weight |
|---|---|---|
| Akeso, Inc. | 9926 | 10.06% |
| Sino Biopharmaceutical Limited | 1177 | 9.78% |
| Innovent Biologics, Inc. | 1801 | 9.66% |
| WuXi AppTec Co., Ltd. | 2359 | 8.81% |
| WuXi Biologics (Cayman) Inc. | 2269 | 8.71% |
| CSPC Pharmaceutical Group Limited | 1093 | 8.52% |
| Hansoh Pharmaceutical Group Company Limited | 3692 | 7.94% |
| Alibaba Health Information Technology Limited | 0241 | 4.93% |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | SFOSF | 4.60% |
| Genscript Biotech Corporation | 1548 | 4.07% |